Who are Intranasal calcitonin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Osteobios, Cibacalcin, Miacalcin, Miacalcin Calcitonin Salmon Nasal Spray, pramlintide acetate (Symlin), Salmon Calcitonin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intranasal-calcitonin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Intranasal calcitonin — Competitive Intelligence Brief

Intranasal calcitonin (Intranasal calcitonin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcitonin receptor agonist. Area: Endocrinology / Bone metabolism.

marketed Calcitonin receptor agonist Calcitonin receptor Endocrinology / Bone metabolism Small molecule Live · refreshed every 30 min

Target snapshot

Intranasal calcitonin (Intranasal calcitonin) — Université de Montréal. Intranasal calcitonin is a peptide hormone that binds to calcitonin receptors on osteoclasts to inhibit bone resorption and increase bone mineral density.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intranasal calcitonin TARGET	Intranasal calcitonin	Université de Montréal	marketed	Calcitonin receptor agonist	Calcitonin receptor
Osteobios	CALCITONIN	Sanofi Aventis Us	marketed	Calcitonin [EPC]	calcitonin receptor	2025-01-01
Cibacalcin	CALCITONIN HUMAN	Novartis	marketed	calcitonin (human synthetic)	Amylin receptor AMY2, Calcitonin receptor, Amylin receptor AMY1	1986-01-01
Miacalcin	calcitonin (salmon synthetic)	Sanofi	marketed	Calcitonin [EPC]	calcitonin receptors	1978-01-01
Miacalcin Calcitonin Salmon Nasal Spray	Miacalcin Calcitonin Salmon Nasal Spray	University of Missouri-Columbia	marketed	Calcitonin receptor agonist	Calcitonin receptor
pramlintide acetate (Symlin)	pramlintide acetate (Symlin)	AstraZeneca	marketed	Amylin receptor agonist	Amylin receptor (calcitonin receptor-like receptor with receptor activity-modifying protein 3)
Salmon Calcitonin	Salmon Calcitonin	Eli Lilly and Company	marketed	Calcitonin receptor agonist	Calcitonin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcitonin receptor agonist class)

Eli Lilly and Company · 1 drug in this class
Tarsa Therapeutics, Inc. · 1 drug in this class
University of Missouri-Columbia · 1 drug in this class
Université de Montréal · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intranasal calcitonin — Competitive Intelligence Brief. https://druglandscape.com/ci/intranasal-calcitonin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab